MeSH term
Frequency | Condition_Probility | Humans | 257 | 0.0 |
Insulin/secretion | 5 | 9.0 |
Research Support, Non-U.S. Gov't | 134 | 0.0 |
Adolescent | 15 | 0.0 |
Adrenalectomy | 2 | 4.0 |
Dexamethasone/diagnostic use | 4 | 10.0 |
Eating/*physiology | 4 | 5.0 |
Female | 130 | 0.0 |
Hydrocortisone/blood/urine | 2 | 16.0 |
In Situ Hybridization | 4 | 0.0 |
Radioimmunoassay | 22 | 1.0 |
Adult | 154 | 0.0 |
Aged | 33 | 0.0 |
Blood Proteins/analysis | 2 | 1.0 |
Eating | 11 | 7.0 |
Male | 156 | 0.0 |
Middle Aged | 89 | 0.0 |
Nutritional Status | 2 | 1.0 |
Obesity/blood | 2 | 5.0 |
Blood Glucose/analysis | 44 | 6.0 |
Case-Control Studies | 7 | 0.0 |
Peptide Fragments/*blood | 8 | 9.0 |
*Postprandial Period | 3 | 10.0 |
Risk Factors | 3 | 0.0 |
Triglycerides/*blood | 2 | 0.0 |
Hamsters | 9 | 0.0 |
Mice | 9 | 0.0 |
Mice, Obese | 3 | 6.0 |
Rats | 15 | 0.0 |
Spectrometry, Mass, Electrospray Ionization | 3 | 3.0 |
Transfection | 7 | 0.0 |
Tumor Cells, Cultured | 4 | 0.0 |
Comparative Study | 50 | 0.0 |
Dietary Fiber/*pharmacology | 2 | 40.0 |
Gastric Emptying/*drug effects | 4 | 30.0 |
Gastric Inhibitory Polypeptide/blood | 31 | 81.0 |
Insulin/blood | 56 | 8.0 |
Peptide Fragments/blood | 2 | 1.0 |
*Triticum | 2 | 40.0 |
C-Peptide/blood | 20 | 11.0 |
Gastric Inhibitory Polypeptide/*pharmacology | 10 | 90.0 |
Glucose Clamp Technique | 6 | 5.0 |
Insulin/blood/*secretion | 22 | 44.0 |
Reference Values | 17 | 0.0 |
Chromatography, Gel | 3 | 0.0 |
Peptide Fragments/*physiology | 3 | 10.0 |
Postprandial Period | 7 | 7.0 |
Protein Precursors/*physiology | 2 | 22.0 |
Spectrum Analysis, Mass/*methods | 2 | 5.0 |
Area Under Curve | 3 | 0.0 |
Blood Glucose/metabolism | 55 | 7.0 |
Fasting/blood | 2 | 3.0 |
Gastric Inhibitory Polypeptide/blood/*secretion | 19 | 100.0 |
Growth Hormone/blood | 3 | 1.0 |
Statistics, Nonparametric | 2 | 0.0 |
Animals | 52 | 0.0 |
Disease Models, Animal | 2 | 0.0 |
Gastric Inhibitory Polypeptide/administration & dosage/*pharmacology | 2 | 100.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 9 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 34 | 0.0 |
Calcium/metabolism | 2 | 0.0 |
DNA Primers | 2 | 0.0 |
Gastric Inhibitory Polypeptide/*metabolism | 6 | 85.0 |
Adenylate Cyclase/metabolism | 3 | 2.0 |
Cells, Cultured | 5 | 0.0 |
Chromatography, High Pressure Liquid | 4 | 0.0 |
Cyclic AMP/metabolism | 5 | 0.0 |
Diabetes Mellitus/*drug therapy | 2 | 18.0 |
Dose-Response Relationship, Drug | 9 | 0.0 |
Gastric Inhibitory Polypeptide/chemistry/*pharmacology | 2 | 100.0 |
Glucose/metabolism | 4 | 1.0 |
Insulin/*secretion | 12 | 15.0 |
Protein Structure, Tertiary | 2 | 0.0 |
Time Factors | 28 | 0.0 |
Administration, Oral | 17 | 1.0 |
Corticotropin/blood | 4 | 2.0 |
Glucose Tolerance Test | 31 | 7.0 |
Hydrocortisone/blood | 5 | 1.0 |
Infusions, Intravenous | 8 | 1.0 |
Injections, Intravenous | 4 | 0.0 |
Amino Acid Sequence | 8 | 0.0 |
Molecular Sequence Data | 9 | 0.0 |
Gastric Inhibitory Polypeptide/*blood | 53 | 96.0 |
Glucose/pharmacology | 14 | 13.0 |
Protein Precursors/*blood | 5 | 6.0 |
Aged, 80 and over | 2 | 0.0 |
Hyperinsulinism/*blood | 2 | 11.0 |
Cell Line | 5 | 0.0 |
*GTP-Binding Protein alpha Subunits, Gi-Go | 2 | 25.0 |
GTP-Binding Protein alpha Subunits, Gs/metabolism | 2 | 13.0 |
Gene Expression Regulation | 2 | 0.0 |
Heterotrimeric GTP-Binding Proteins/genetics/*metabolism | 2 | 28.0 |
Proto-Oncogene Proteins/genetics/*metabolism | 2 | 0.0 |
RNA, Messenger/*metabolism | 2 | 0.0 |
Gastric Inhibitory Polypeptide/*physiology | 6 | 100.0 |
Hyperplasia | 2 | 0.0 |
RNA, Messenger/analysis | 2 | 0.0 |
Analysis of Variance | 4 | 0.0 |
Glucagon/blood | 21 | 22.0 |
Duodenum/metabolism | 2 | 5.0 |
Gastrins/metabolism | 2 | 10.0 |
Somatostatin/metabolism | 2 | 4.0 |
Vasoactive Intestinal Peptide/metabolism | 5 | 7.0 |
English Abstract | 9 | 0.0 |
Restriction Mapping | 2 | 0.0 |
Amino Acids/analysis | 2 | 0.0 |
Clone Cells | 2 | 0.0 |
Cyclic AMP/biosynthesis | 2 | 1.0 |
Receptors, Gastrointestinal Hormone/*metabolism | 2 | 7.0 |
Cricetulus | 2 | 0.0 |
Gene Frequency | 2 | 0.0 |
Kinetics | 23 | 0.0 |
Metabolic Clearance Rate | 4 | 1.0 |
Gastric Emptying/physiology | 2 | 11.0 |
Gastrointestinal Hormones/*blood | 59 | 59.0 |
Postprandial Period/physiology | 3 | 16.0 |
Body Mass Index | 2 | 0.0 |
Follow-Up Studies | 2 | 0.0 |
Gastric Inhibitory Polypeptide/metabolism | 9 | 90.0 |
Glucagon/metabolism | 6 | 22.0 |
Glucose/*metabolism | 3 | 1.0 |
Insulin/metabolism | 4 | 2.0 |
Peptide Fragments/metabolism | 3 | 0.0 |
Protein Precursors/metabolism | 3 | 2.0 |
Glucagon/*blood | 4 | 22.0 |
Glucose/*administration & dosage | 8 | 33.0 |
Liver/metabolism | 3 | 0.0 |
Antigens, CD26/metabolism | 3 | 23.0 |
Renal Dialysis | 4 | 1.0 |
Fasting | 19 | 6.0 |
Glucose/*pharmacology | 5 | 6.0 |
Peptides/*blood | 3 | 4.0 |
CHO Cells | 2 | 0.0 |
Enzyme Activation/drug effects | 2 | 0.0 |
Signal Transduction/physiology | 2 | 0.0 |
Cholecystokinin/analysis | 3 | 30.0 |
Enteroglucagon/analysis | 2 | 33.0 |
Fluorescent Antibody Technique | 2 | 0.0 |
Gastrointestinal Hormones/*analysis | 4 | 14.0 |
Serotonin/analysis | 2 | 8.0 |
Blood Glucose/*metabolism | 14 | 5.0 |
Gastrointestinal Hormones/*physiology | 6 | 40.0 |
Insulin/*blood | 26 | 15.0 |
Gastric Inhibitory Polypeptide/*secretion | 13 | 92.0 |
Gastrointestinal Hormones/*secretion | 23 | 60.0 |
Glucose/*diagnostic use | 3 | 42.0 |
Peptide Fragments/*secretion | 2 | 28.0 |
Peptides/*secretion | 2 | 15.0 |
Secretory Rate/drug effects | 4 | 4.0 |
Stimulation, Chemical | 4 | 0.0 |
Age Factors | 2 | 0.0 |
Diabetes Mellitus/*metabolism | 3 | 8.0 |
Gastric Inhibitory Polypeptide/blood/*metabolism | 2 | 100.0 |
Sex Factors | 2 | 0.0 |
Fatty Acids, Nonesterified/blood | 3 | 1.0 |
Islets of Langerhans/*metabolism | 4 | 7.0 |
Protein Precursors/blood | 2 | 5.0 |
Triglycerides/blood | 6 | 0.0 |
Cushing Syndrome/*etiology | 3 | 25.0 |
*Food | 8 | 8.0 |
Gene Expression | 3 | 0.0 |
Dietary Carbohydrates/pharmacology | 2 | 11.0 |
Dietary Fats/pharmacology | 2 | 5.0 |
Obesity/*metabolism | 6 | 8.0 |
Galactans/*pharmacology | 2 | 100.0 |
Mannans/*pharmacology | 2 | 40.0 |
Base Sequence | 4 | 0.0 |
Binding, Competitive | 2 | 0.0 |
Gene Library | 2 | 0.0 |
Pancreatic Neoplasms/*metabolism | 2 | 2.0 |
Sequence Homology, Amino Acid | 3 | 0.0 |
Swine | 13 | 0.0 |
Diabetes Mellitus, Type 2/*blood/drug therapy | 2 | 11.0 |
Glucose/administration & dosage/*pharmacology | 5 | 41.0 |
Cloning, Molecular | 2 | 0.0 |
Linkage (Genetics) | 2 | 0.0 |
Dietary Proteins/pharmacology | 2 | 20.0 |
Pancreas/metabolism | 2 | 2.0 |
Peptide Fragments/*pharmacology | 4 | 2.0 |
Sincalide/*pharmacology | 3 | 30.0 |
Glucose/diagnostic use | 4 | 28.0 |
*Eating | 4 | 6.0 |
Energy Intake | 3 | 1.0 |
Gastrins/*secretion | 2 | 28.0 |
In Vitro | 5 | 0.0 |
Diabetes Mellitus, Type 2/blood/*physiopathology | 2 | 10.0 |
Cattle | 2 | 0.0 |
Insulin/blood/secretion | 7 | 33.0 |
Sequence Homology, Nucleic Acid | 2 | 0.0 |
Species Specificity | 5 | 0.0 |
Syndrome | 2 | 0.0 |
Gastric Inhibitory Polypeptide/pharmacology | 2 | 40.0 |
RNA, Messenger/genetics | 2 | 0.0 |
Chronic Disease | 5 | 0.0 |
Diabetes Mellitus, Type 2/*physiopathology | 2 | 6.0 |
Obesity/*physiopathology | 3 | 5.0 |
Pancreatitis/*physiopathology | 2 | 40.0 |
Dogs | 8 | 0.0 |
Glucagon/blood/*secretion | 3 | 75.0 |
Models, Biological | 2 | 0.0 |
Peptide Fragments/blood/*secretion | 3 | 60.0 |
Peptides/blood/*secretion | 2 | 100.0 |
Diabetes Mellitus, Type 2/*blood | 4 | 3.0 |
Insulin/*blood/secretion | 4 | 33.0 |
Structure-Activity Relationship | 4 | 0.0 |
Eating/physiology | 2 | 3.0 |
Gastric Inhibitory Polypeptide/pharmacology/*physiology | 2 | 100.0 |
Gastric Inhibitory Polypeptide/*blood/secretion | 6 | 85.0 |
Immune Sera | 4 | 1.0 |
Rabbits | 3 | 0.0 |
Glucose/administration & dosage | 5 | 16.0 |
Sucrose/*pharmacology | 2 | 50.0 |
Pancreatic Hormones/*blood | 5 | 55.0 |
Gastric Acid/*secretion | 3 | 4.0 |
Hormones/pharmacology | 2 | 4.0 |
*Pancreatectomy | 2 | 22.0 |
Cholecystokinin/*pharmacology | 2 | 8.0 |
Glucagon/blood/secretion | 2 | 100.0 |
Pancreatic Polypeptide/blood/secretion | 2 | 28.0 |
C-Peptide/*blood | 3 | 8.0 |
Double-Blind Method | 5 | 0.0 |
Duodenum | 2 | 8.0 |
*Enteral Nutrition | 2 | 8.0 |
Gastrins/*blood | 2 | 4.0 |
Hydrogen-Ion Concentration | 2 | 0.0 |
Jejunum | 2 | 18.0 |
Child | 5 | 0.0 |
Child, Preschool | 3 | 0.0 |
Food | 14 | 11.0 |
Gastric Inhibitory Polypeptide/blood/*pharmacology | 5 | 100.0 |
Dietary Fats | 3 | 7.0 |
Hyperglycemia/blood | 2 | 22.0 |
Glucagon/secretion | 3 | 50.0 |
Perfusion | 2 | 0.0 |
Phentolamine/pharmacology | 2 | 9.0 |
Propranolol/pharmacology | 2 | 4.0 |
Blood Glucose/*analysis | 4 | 3.0 |
Drug Evaluation | 2 | 0.0 |
*Diet | 2 | 0.0 |
*Gastric Emptying | 3 | 30.0 |
Islets of Langerhans/*secretion | 3 | 27.0 |
Infant | 2 | 0.0 |
Random Allocation | 4 | 0.0 |
Diarrhea/chemically induced | 2 | 8.0 |
Xylitol/adverse effects/*pharmacology | 2 | 100.0 |
Adipose Tissue/metabolism | 3 | 2.0 |
Cats | 2 | 0.0 |
Gastric Acid/secretion | 4 | 8.0 |
Liver/drug effects/metabolism | 2 | 2.0 |
Obesity/metabolism | 2 | 4.0 |
Enteral Nutrition | 3 | 12.0 |
Pregnancy | 5 | 0.0 |
Pepsin A/secretion | 2 | 33.0 |
Secretory Rate | 2 | 6.0 |
*Diet, Reducing | 2 | 2.0 |
Diabetes Mellitus, Type 2/*metabolism | 2 | 4.0 |
Neurotensin/blood | 3 | 42.0 |
Dietary Fats/*pharmacology | 6 | 9.0 |
Gastric Inhibitory Polypeptide/*physiology/secretion | 2 | 100.0 |
Motilin/blood | 5 | 27.0 |
Pancreatic Polypeptide/blood | 12 | 20.0 |
Somatostatin/blood | 3 | 12.0 |
Vasoactive Intestinal Peptide/blood | 5 | 12.0 |
Glucose/administration & dosage/pharmacology | 2 | 16.0 |
Secretin/blood | 3 | 30.0 |
Blood Glucose | 5 | 6.0 |
Diabetes Mellitus/etiology | 2 | 18.0 |
Cell Membrane/metabolism | 2 | 0.0 |
Pancreatic Polypeptide/*secretion | 2 | 40.0 |
Duodenum/analysis | 3 | 25.0 |
Gastrointestinal Hormones/*metabolism | 5 | 20.0 |
Rats, Inbred Strains | 5 | 0.0 |
Hormones/*blood | 4 | 2.0 |
Atropine/*pharmacology | 2 | 11.0 |
Obesity/*blood | 3 | 3.0 |
Infusions, Parenteral | 10 | 7.0 |
Secretin/*pharmacology | 3 | 25.0 |
Gastric Inhibitory Polypeptide/*blood/physiology | 3 | 100.0 |
Enteroglucagon/metabolism | 2 | 66.0 |
*Vagotomy | 3 | 60.0 |
Receptors, Cell Surface/*metabolism | 2 | 0.0 |
Receptors, Vasoactive Intestinal Peptide | 2 | 3.0 |
Dietary Fiber/*metabolism | 2 | 40.0 |
Feedback | 3 | 1.0 |
Insulin/*diagnostic use | 2 | 10.0 |
Insulin Infusion Systems | 2 | 7.0 |
Somatostatin/*blood | 2 | 11.0 |
Diabetes Mellitus, Type 1/*blood | 2 | 1.0 |
*Fasting | 6 | 24.0 |
Insulin/blood/therapeutic use | 2 | 33.0 |
Insulin/*therapeutic use | 3 | 3.0 |
Body Weight | 3 | 0.0 |
Gastric Emptying | 2 | 14.0 |
Intestinal Absorption | 2 | 1.0 |
Glucagon/pharmacology | 2 | 6.0 |
Duodenum/*physiology | 2 | 18.0 |
Dietary Carbohydrates/*pharmacology | 2 | 9.0 |
Dietary Proteins/*pharmacology | 2 | 15.0 |
Gastric Acidity Determination | 2 | 9.0 |
Motilin/secretion | 2 | 100.0 |
Secretin/analysis | 2 | 66.0 |
Gastrins/blood | 9 | 12.0 |
Obesity/blood/*therapy | 2 | 100.0 |
Stomach/*surgery | 2 | 50.0 |
Chemistry | 2 | 0.0 |
Intestines/*analysis | 2 | 25.0 |
Duodenum/*metabolism | 3 | 15.0 |
Gastric Inhibitory Polypeptide/*isolation & purification | 2 | 100.0 |
Gastrointestinal Hormones/*isolation & purification | 2 | 100.0 |
Gastrointestinal Hormones/*pharmacology | 5 | 17.0 |
*Pregnancy | 2 | 1.0 |
Pregnancy in Diabetics/*blood | 2 | 5.0 |
Clinical Trials | 2 | 0.0 |
Gastric Inhibitory Polypeptide/blood/*pharmacology/physiology | 2 | 100.0 |
Fats/*administration & dosage/metabolism | 2 | 100.0 |
Body Composition | 2 | 0.0 |
Cholesterol/blood | 2 | 0.0 |
*Exertion | 2 | 1.0 |
Hyperinsulinism/blood | 2 | 18.0 |
Obesity/*blood/therapy | 2 | 50.0 |
Pancreatic Polypeptide/*blood | 3 | 15.0 |
Absorption | 2 | 1.0 |
Dietary Carbohydrates/*metabolism | 2 | 18.0 |
Enteroglucagon/blood | 4 | 57.0 |
Gastric Inhibitory Polypeptide/*analysis | 2 | 100.0 |
Histocytochemistry | 3 | 0.0 |
Gastrectomy | 2 | 3.0 |
Gastric Inhibitory Polypeptide/blood/*physiology | 3 | 100.0 |
Atrophy | 2 | 1.0 |
Diabetes Mellitus/*blood | 4 | 4.0 |
Gastric Inhibitory Polypeptide/secretion | 3 | 75.0 |
Gastrins/secretion | 2 | 15.0 |
Pancreatic Polypeptide/secretion | 2 | 25.0 |
Glucose/administration & dosage/*diagnostic use | 2 | 100.0 |
*Circadian Rhythm | 2 | 0.0 |
Cross-Over Studies | 2 | 0.0 |
Infant, Newborn | 2 | 0.0 |
Peptides | 2 | 3.0 |
Jejunum/surgery | 2 | 50.0 |
Diabetes Mellitus/*physiopathology | 3 | 15.0 |
Insulin/*pharmacology | 2 | 0.0 |
Antigens | 2 | 2.0 |
Kidney/*metabolism | 2 | 1.0 |
Renal Veins | 2 | 50.0 |
Duodenum/*secretion | 2 | 50.0 |
Ileum/*surgery | 3 | 27.0 |
Jejunum/*surgery | 2 | 20.0 |
Molecular Weight | 2 | 0.0 |
Secretin/*blood | 2 | 40.0 |
Vasoactive Intestinal Peptide/*blood | 2 | 2.0 |
Gastric Juice/*secretion | 2 | 18.0 |
Guinea Pigs | 2 | 0.0 |
Cortisone/blood | 2 | 28.0 |
Somatomedins/blood | 2 | 40.0 |
Testosterone/blood | 2 | 0.0 |
Thyrotropin/blood | 2 | 0.0 |
Hypoglycemic Agents/*therapeutic use | 2 | 3.0 |
Protein Binding | 2 | 0.0 |
Intestine, Small/*secretion | 2 | 66.0 |
*Obesity | 3 | 5.0 |
